PENNATI, MARZIA
PENNATI, MARZIA
Universita' degli Studi di MILANO
Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy
2018 N. Bedini, A. Cicchetti, F. Palorini, T. Magnani, V. Zuco, M. Pennati, E. Campi, P. Allavena, S. Pesce, S. Villa, B. Avuzzi, S. Morlino, M.E. Visentin, N. Zaffaroni, T. Rancati, R. Valdagni
Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads
2017 I. D'Annessa, S. Sattin, J. Tao, M. Pennati, C. Sànchez Martìn, E. Moroni, A. Rasola, N. Zaffaroni, D.A. Agard, A. Bernardi, G. Colombo
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial
2014 A. Necchi, P. Giannatempo, L. Mariani, E. Farè, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchianò, N. Nicolai, M. Maffezzini, E. Togliardi, M.G. Daidone, A.M. Gianni, R. Salvioni, F. De Braud
MiR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells
2014 M. Pennati, A. Lopergolo, V. Profumo, M. De Cesare, S. Sbarra, R. Valdagni, N. Zaffaroni, P. Gandellini, M. Folini
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
2012 A. Necchi, L. Mariani, N. Zaffaroni, L.H. Schwartz, P. Giannatempo, F. Crippa, C. Morosi, R. Lanocita, T. Sava, C. Ortega, C. Messina, C. Sacco, M. Pennati, M.G. Daidone, N. Nicolai, F. De Braud, A.M. Gianni, R. Salvioni
miR-21: an oncomir on strike in prostate cancer
2010 M. Folini, P. Gandellini, N. Longoni, V. Profumo, M. Callari, M. Pennati, M. Colecchia, R. Supino, S. Veneroni, R. Salvioni, R. Valdagni, M. Daidone, N. Zaffaroni